GC0000105A - Calcium (3S) tetrahydro-3-furanyl (1S, 2R)-3-ÄÄ(4-aminophenyl) sulfonylÜ(isobutyl) aminoÜ-1-benzyl-2-(phosphonooxy) propylcarbamate. - Google Patents

Calcium (3S) tetrahydro-3-furanyl (1S, 2R)-3-ÄÄ(4-aminophenyl) sulfonylÜ(isobutyl) aminoÜ-1-benzyl-2-(phosphonooxy) propylcarbamate.

Info

Publication number
GC0000105A
GC0000105A GCP1999203A GC0000105A GC 0000105 A GC0000105 A GC 0000105A GC P1999203 A GCP1999203 A GC P1999203A GC 0000105 A GC0000105 A GC 0000105A
Authority
GC
Cooperation Council for the Arab states of the Gulf
Prior art keywords
sulfonylü
aminoü
propylcarbamate
phosphonooxy
aminophenyl
Prior art date
Application number
Other languages
English (en)
Inventor
Ian Gordon Armitage
Hardev Singh
Andrew David Searle
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of GC0000105A publication Critical patent/GC0000105A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GCP1999203 1998-07-18 1999-07-14 Calcium (3S) tetrahydro-3-furanyl (1S, 2R)-3-ÄÄ(4-aminophenyl) sulfonylÜ(isobutyl) aminoÜ-1-benzyl-2-(phosphonooxy) propylcarbamate. GC0000105A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
GC0000105A true GC0000105A (en) 2005-06-29

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
GCP1999203 GC0000105A (en) 1998-07-18 1999-07-14 Calcium (3S) tetrahydro-3-furanyl (1S, 2R)-3-ÄÄ(4-aminophenyl) sulfonylÜ(isobutyl) aminoÜ-1-benzyl-2-(phosphonooxy) propylcarbamate.

Country Status (47)

Country Link
US (3) US6514953B1 (pl)
EP (2) EP1240903A3 (pl)
JP (1) JP3437553B2 (pl)
KR (1) KR100694721B1 (pl)
CN (1) CN1188422C (pl)
AP (1) AP2001002039A0 (pl)
AR (1) AR019388A1 (pl)
AT (1) ATE229964T1 (pl)
AU (1) AU766056B2 (pl)
BG (1) BG105253A (pl)
BR (1) BRPI9912156B8 (pl)
CA (1) CA2337857C (pl)
CO (1) CO5090836A1 (pl)
CZ (1) CZ300447B6 (pl)
DE (1) DE69904600T2 (pl)
DK (1) DK1098898T3 (pl)
DZ (1) DZ2845A1 (pl)
EA (1) EA003191B1 (pl)
EE (1) EE200100038A (pl)
ES (1) ES2189450T3 (pl)
GB (1) GB9815567D0 (pl)
GC (1) GC0000105A (pl)
GE (1) GEP20033030B (pl)
GT (1) GT199900111A (pl)
HR (1) HRP20010046A2 (pl)
HU (1) HU229700B1 (pl)
ID (1) ID28070A (pl)
IL (1) IL140824A (pl)
IS (1) IS5808A (pl)
JO (1) JO2114B1 (pl)
MA (1) MA26660A1 (pl)
MY (1) MY122323A (pl)
NO (1) NO329676B1 (pl)
NZ (1) NZ509291A (pl)
OA (1) OA11706A (pl)
PA (1) PA8477801A1 (pl)
PE (1) PE20000869A1 (pl)
PL (1) PL195736B1 (pl)
PT (1) PT1098898E (pl)
SK (1) SK285311B6 (pl)
SV (1) SV1999000096A (pl)
TN (1) TNSN99145A1 (pl)
TR (1) TR200100111T2 (pl)
TW (1) TWI245770B (pl)
WO (1) WO2000004033A1 (pl)
YU (1) YU3401A (pl)
ZA (1) ZA200100417B (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
CA2386850C (en) * 1999-10-06 2010-03-30 Piet Tom Bert Paul Wigerinck Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
TW200408645A (en) * 2002-04-26 2004-06-01 Gilead Sciences Inc Non nucleoside reverse transcriptase inhibitors
PT1575951E (pt) 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
EP1620109A2 (en) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv
WO2005042773A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
BRPI0417988A (pt) 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
WO2010134045A1 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
US20120208787A1 (en) 2009-06-30 2012-08-16 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
US9085592B2 (en) * 2009-09-16 2015-07-21 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
WO2011085130A1 (en) 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
WO2011158259A1 (en) 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
WO2012032389A2 (en) 2010-09-10 2012-03-15 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
IN2012DE00082A (pl) 2012-01-10 2015-05-01 Council Scient Ind Res
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
EP1042280A2 (en) * 1997-12-24 2000-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
HK1040625B (zh) * 1998-11-04 2005-04-01 法玛西雅厄普约翰美国公司 用於改善替普拉那维的药物动力学的方法
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ES2295068T3 (es) * 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.

Also Published As

Publication number Publication date
PL345620A1 (en) 2002-01-02
ATE229964T1 (de) 2003-01-15
HK1034261A1 (en) 2001-10-19
DZ2845A1 (fr) 2003-12-01
OA11706A (en) 2005-01-13
CN1324363A (zh) 2001-11-28
BG105253A (en) 2001-12-29
AR019388A1 (es) 2002-02-13
EP1240903A2 (en) 2002-09-18
PA8477801A1 (es) 2000-05-24
EP1240903A3 (en) 2003-02-12
HRP20010046A2 (en) 2002-02-28
CZ300447B6 (cs) 2009-05-20
PE20000869A1 (es) 2000-09-08
EP1098898A1 (en) 2001-05-16
IS5808A (is) 2001-01-12
JP3437553B2 (ja) 2003-08-18
US20030096795A1 (en) 2003-05-22
NO20010282L (no) 2001-03-07
PL195736B1 (pl) 2007-10-31
AP2001002039A0 (en) 2001-03-31
IL140824A (en) 2004-09-27
DE69904600D1 (de) 2003-01-30
PT1098898E (pt) 2003-04-30
EE200100038A (et) 2002-06-17
ID28070A (id) 2001-05-03
BRPI9912156B8 (pt) 2021-05-25
ZA200100417B (en) 2002-02-27
EA200100053A1 (ru) 2001-08-27
EA003191B1 (ru) 2003-02-27
CA2337857A1 (en) 2000-01-27
EP1098898B1 (en) 2002-12-18
MY122323A (en) 2006-04-29
DE69904600T2 (de) 2003-11-13
MA26660A1 (fr) 2004-12-20
CN1188422C (zh) 2005-02-09
HUP0103432A3 (en) 2003-01-28
TNSN99145A1 (fr) 2005-11-10
NZ509291A (en) 2003-05-30
JO2114B1 (en) 2000-05-21
SV1999000096A (es) 2000-07-06
AU766056B2 (en) 2003-10-09
NO329676B1 (no) 2010-11-29
GT199900111A (es) 2001-01-05
ES2189450T3 (es) 2003-07-01
BR9912156A (pt) 2001-04-10
GEP20033030B (en) 2003-07-25
AU5037999A (en) 2000-02-07
TR200100111T2 (tr) 2002-02-21
CA2337857C (en) 2011-01-25
CO5090836A1 (es) 2001-10-30
WO2000004033A1 (en) 2000-01-27
YU3401A (sh) 2005-06-10
SK762001A3 (en) 2001-10-08
DK1098898T3 (da) 2003-04-07
KR100694721B1 (ko) 2007-03-15
HU229700B1 (en) 2014-05-28
BRPI9912156B1 (pt) 2016-07-26
US6514953B1 (en) 2003-02-04
HUP0103432A2 (hu) 2002-04-29
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
SK285311B6 (sk) 2006-10-05
NO20010282D0 (no) 2001-01-17
GB9815567D0 (en) 1998-09-16
IL140824A0 (en) 2002-02-10
CZ2001219A3 (cs) 2001-07-11
JP2003521447A (ja) 2003-07-15
TWI245770B (en) 2005-12-21

Similar Documents

Publication Publication Date Title
DZ2845A1 (fr) Calcium (3S) tétrahydro-3-furanyle(1S,2R)-3-ÄÄ(4-aminophényle)sulfonyleÜ(sobutyle)aminoÜ-1-benzyle-2(phosphonooxy)propylcarbamate.
DZ2737A1 (fr) Catalyseurs de polymérisation.
ZA997794B (en) Prostaglandin product.
ZA996185B (en) Sulfanylsilanes.
ZA976242B (en) Illudin analogs useful as antitumor agents.
ZA996648B (en) Novel proteins from actinobacillus pleuropneumoniae.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA99473B (en) New naphthyl- and anilide-substituted sulphonamides.
ZA991268B (en) Novel sulfonamides.
AU5818100A (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate
ITTO950478A0 (it) Rotore per elicotteri.
ES1047984Y (es) Corchete de ortodoncia.
SI1098898T1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
IT1304991B1 (it) Cavo di comando flessibile, particolarmente per cambi di autoveicoli.
GB0127965D0 (en) Variable speed P.T.O driven axle(s)
ZA991537B (en) Catalyst composition.
ZA992062B (en) Rotary Springkler.
ES1041422Y (es) Dispositivo emparejador de unidades de calzado.
TW335892U (en) Measuring device for feather curves, arch degrees
ZA978278B (en) Drawing instruments.
ITMO970060A0 (it) Botola, particolarmente per veicoli.
ZA991090B (en) Dynamic weighing system.
ZA981308B (en) 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thones.
AUPO527697A0 (en) The S.C.B.S. jackpots
ZA200007177B (en) Motion transmission devices.